In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of treatment Tirzepatide users experienced greater waistline reduction (7.2 inches vs.

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in adults with obesity but without diabetes. Over 72 weeks, tirzepatide helped more participants reach key weight loss milestones,

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater weight loss compared to semaglutide. This landmark finding